MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888 ...

Key Takeaways PACB announced innovations to its Revio and Vega platforms, centered on SPRQ-Nx sequencing chemistry.PACB's SPRQ-Nx boosts efficiency with more runs per system and reduced waste.PacBio's Revio with SPRQ-Nx enables low-cost long-read genomes for population-scale research.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, announced innovations to its Revio and Vega platforms last week. The innovations are expected to lower sequencing costs, add new multiomic capabilities ...

Company Overview - Pacific Biosciences of California (PACB) ended the recent trading session at $1.59, reflecting a -1.85% change from the previous day's closing price, which lagged behind the S&P 500's 0.16% loss [1] - Prior to this trading session, shares of Pacific Biosciences had gained 35%, significantly outperforming the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14% [1] Earnings Projections - The upcoming earnings release is projected to show an EPS of -$0.16, indicating a 5.88% increase compared to the same quarter of the previous year [2] - Revenue is anticipated to be $39.84 million, reflecting a 0.33% decrease from the same quarter last year [2] - For the full year, analysts expect earnings of -$0.56 per share and revenue of $158.66 million, marking changes of +32.53% and +3.02% respectively from last year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Pacific Biosciences are important as they indicate changing near-term business trends, with positive revisions reflecting analyst optimism about the business and profitability [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with a consensus EPS projection having moved 5.88% higher in the past 30 days [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [7] - The Zacks Industry Rank assesses the strength of specific industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scaleMENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chemistry and consumables, whic ...

Core Insights - PacBio's HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference Project, a significant initiative led by the Korea Disease Control and Prevention Agency and the National Institute of Health [1][3] - The project aims to create the first large-scale, telomere-to-telomere quality reference genomes for the Korean population, contributing to the global Human Pangenome Reference Consortium [2][3] - This initiative is expected to enhance the understanding of population-specific genetic variants, improve insights into unexplained diseases, and support the development of precision diagnostics and therapies [2][3] Company Overview - PacBio is a leading life science technology company that specializes in advanced sequencing solutions, including HiFi long-read sequencing, addressing complex genetic problems across various research applications [5] - The company provides an integrated sequencing solution that combines accuracy, completeness, and resolution across DNA and RNA, marking the first national pangenome initiative to adopt its full technology suite [4][8] Project Details - The Korean Pangenome Project was announced on September 5, 2024, with a goal of sequencing more than 1,000 whole genomes, expanding from a pilot program that involved 200 researchers and academic participants [3] - The project will capture the unique genetic diversity of the Korean population and integrate this data into international reference standards, thereby advancing disease and evolutionary research [3][4]

Core Insights - PacBio has expanded its partnership with seqWell to distribute the LongPlex Multiplexing Kit, enhancing its sequencing solutions portfolio with global availability expected by 2026 [1][10] Company Developments - The LongPlex Multiplexing Kit is designed for scalable and efficient sample preparation, optimized for PacBio's HiFi sequencing, and supports high-throughput applications [2][6] - The collaboration aims to provide customers with more workflow options, complementing PacBio's long-read technology [6][7] - PacBio's management anticipates that the partnership will enhance customer choice and facilitate rapid, economical data generation [7][10] Financial Performance - Following the announcement of the partnership, PacBio's shares declined by nearly 7.9% [4] - The company has a market capitalization of $420.5 million and an estimated growth rate of 27.7% for 2025, with a recent earnings surprise of 27.8% [5] Industry Prospects - The global sequencing market is projected to grow from $15,540 million in 2023 to $62,478.8 million by 2030, with a CAGR of 22.2%, driven by increasing demand for gene therapy and consumer genomics [8] - The expanded partnership is expected to significantly boost PacBio's business in this growing market [8]

Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to dateMENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate comprehensive genomic and epigenomic data from as many as 7,800 participants. The ef ...

Core Insights - PacBio has expanded its partnership with seqWell to distribute the LongPlex™ Multiplexing Kit, enhancing sample preparation for various genomic sequencing applications [1][5] - The LongPlex™ kit is designed for high-throughput, cost-effective sample preparation, enabling efficient DNA fragmentation and multiplexing for up to hundreds of samples in a single run [2][4] - This collaboration aims to provide researchers with flexible and rapid solutions for population-scale genomic studies, supporting diverse fields such as low-pass whole genome sequencing and microbial sequencing [3][4] Company Overview - PacBio is a leading life science technology company focused on advanced sequencing solutions, addressing complex genetic problems across various research applications [7] - seqWell specializes in scalable genomics technologies that simplify library preparation workflows, catering to the throughput and cost demands of modern genomics [9] - Veil Genomics, a partner organization, is dedicated to population-scale low-pass whole genome sequencing and aims to democratize genomic insights through innovative sequencing pipelines [11]

Company Performance - Pacific Biosciences of California (PACB) ended the recent trading session at $1.52, showing a +2.01% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.37% [1] - Prior to today's trading, shares of Pacific Biosciences had gained 17.32%, significantly exceeding the Medical sector's gain of 5.9% and the S&P 500's gain of 4.26% [1] Earnings Forecast - The upcoming earnings disclosure is anticipated to show an EPS of -$0.16, reflecting a 5.88% growth compared to the same quarter last year [2] - Revenue is forecasted to be $40.38 million, indicating a 1.03% growth compared to the corresponding quarter of the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of -$0.6 per share and revenue of $158.75 million, representing changes of +27.71% and +3.07% respectively from last year [3] Analyst Sentiment - Recent adjustments to analyst estimates for Pacific Biosciences are indicative of shifting short-term business dynamics, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Pacific Biosciences as 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, holds a Zacks Industry Rank of 144, placing it in the bottom 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - PacBio (PACB) has entered the high-throughput carrier screening market with its expanded PureTarget portfolio, utilizing HiFi sequencing technology to streamline genetic testing into a single scalable assay [1][3][6] Company Developments - The updated PureTarget panels can process up to 100,000 samples annually on a single Revio system, making them suitable for various applications, including clinical programs and national initiatives [2][4] - The new offering addresses the bottleneck of fragmented tests for analyzing difficult hereditary genes, enhancing efficiency and reducing costs for laboratories [3][4] - PacBio's PureTarget panels are available in flexible kit formats (24 and 96-sample kits) tailored for reproductive health and neurological disease, allowing profitable high-throughput programs within existing reimbursement structures [5][9] Industry Prospects - The global carrier screening market was valued at $1.2 billion in 2022 and is projected to grow at a CAGR of 12.4% from 2023 to 2030, driven by increasing demand for genetic testing [7][8] - Government and private sector investments are expected to further propel market expansion, with a focus on cost-efficient technologies and innovative tests [8]